Cell Signaling Technology

Product Pathways - Tyrosine Kinase/ Adaptors

Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide #1254

Description

This peptide is used to block Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb #2243 reactivity.

Quality Control

The quality of the peptide was evaluated by reverse-phase HPLC and by mass spectrometry. The peptide blocks Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb # 2243 signal in immunohistochemistry.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human renal adenocarcinoma, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb (#2243) in the presence of contol peptide (left) or Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide (right).

Applications

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols.

Directions for Use

For Immunohistochemistry, add twice the volume of peptide as volume of antibody used in a 100 ul total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the Phospho-HER2/ErbB2 (Tyr 1221/1222) Antibody #2249 and Phospho HER2/ErbB2 (Tyr 1221/1222)(6B12) Rabbit mAb #2243 data sheets.

Background

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas with the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway as one potential therapeutic strategy.Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 areTyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).

  1. Muthuswamy, S.K. et al. (1999) Mol. Cell. Biol. 19, 6845-6857.
  2. Qian, X. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 1500-1504.
  3. Dittadi, R. and Gion, M. (2000) J. Natl. Cancer Inst. 92, 1443-1444.
  4. Klapper, L.N. et al. (2000) Cancer Res. 60, 3384-3388.
  5. Kwon, Y.K. et al. (1997) J. Neurosci. 17, 8293-8299.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes